在哺乳动物细胞中选择性抑制激酶活性,通过生物对等的配体连接
Jinghao Chen1,2, Yang Huang1,3, Wen-Biao Gan4
1Institute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen, China.
Methods in molecular biology (Clifton, N.J.)
|June 5, 2023
概括
化学遗传方法使得哺乳动物细胞中的快速,选择性酶抑制成为可能. 通过iBOLT方法,将生物对等组遗传地纳入目标激酶以进行精确的抑制,帮助疾病研究和药物开发.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 酶对于细胞过程至关重要;它们的功能障碍与人类疾病有关.
- 酶抑制研究对于理解生理作用和开发药物至关重要.
- 化学遗传方法在哺乳动物细胞中的快速和选择性酶抑制方面具有优势.
研究的目的:
- 描述一种新型化学遗传方法,即iBOLT (通过生物直角连接体的抑制),用于哺乳动物细胞中的快速和选择性激酶抑制.
- 为了证明iBOLT的适用性,使用cAMP依赖的蛋白激酶催化子单元α (PKA-Cα) 作为模型.
- 为抑制各种类激酶提供一个多功能平台.
主要方法:
- 通过遗传密码扩展将非正规的氨基酸与生物对等组遗传地纳入目标激酶.
- 合成一种结合物,将一个互补的生物对等组与已知的抑制性连接体连接起来.
- 通过修改后的激酶和结合物之间的生物对等结合来促进选择性激酶抑制.
主要成果:
- 使用iBOLT方法证明了PKA-Cα的成功和选择性抑制.
- 验证了通过生物 orthogonal 配体连接抑制蛋白质功能的原理.
- 建立了一个广泛适用的化学遗传激酶抑制策略的概念验证.
结论:
- 该iBOLT方法为哺乳动物细胞中激酶的快速和选择性抑制提供了一个强大的工具.
- 这种方法促进了在生理学背景下对酶功能的研究,并有助于药物发现.
- iBOLT可适应针对广泛的激酶,在生物研究中具有广泛的实用性.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K


